At present, the additional time and financial resources required for performing immunohistochemical tests for Ki67 are not justified as this proliferation marker remains inferior to the mitotic rate in predicting the outcomes of patients with cutaneous melanomas. The gene discussed is MKI67; the disease is cutaneous melanoma.